Navigation Links
Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Date:11/28/2007

SOUTH SAN FRANCISCO, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold its Third Annual R&D Day on Wednesday, December 5, 2007 from 10:00 a.m. ET / 7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. PT in New York. The company will discuss updates to its development pipeline, its collaborations, including those with GSK, BMS and Genentech, and its financial outlook for 2007.

Speakers:

-- George Scangos, PhD, President & Chief Executive Officer of Exelixis,

Inc.

-- Michael Morrissey, PhD, President of Research & Development of

Exelixis, Inc.

-- Frank Karbe, Executive Vice President & Chief Financial Officer of

Exelixis, Inc.

-- Peter Lamb, PhD, Senior Vice President, Discovery Research & Chief

Scientific Officer of Exelixis, Inc.

-- Gisela Schwab, MD, Senior Vice President and Chief Medical Officer of

Exelixis, Inc.

-- Steven Sherman, MD of MD Anderson Cancer Center

-- Vince Miller, MD of Memorial Sloan-Kettering Cancer Center

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archive of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on January 4, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is: 21270665.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
2. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
3. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
4. Exelixis Announces Closing of Public Offering of Common Stock
5. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
6. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
7. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
8. Exelixis Sells 80% Stake in Artemis to Taconic
9. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
10. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
11. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 17, 2017 , ... ... stress expertise, and further enhances its scientific power by providing investigators access ... Ph.D., has agreed to join the scientific advisory board. “We are committed ...
(Date:5/18/2017)... ... May 17, 2017 , ... Many complicated neurological ... to develop Alzheimer’s disease, while men are at greater risk for Parkinson’s disease. ... bias is the aim of a research program at Worcester Polytechnic Institute (WPI) ...
(Date:5/16/2017)... ... May 16, 2017 , ... ... has released its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing ... test is designed to quickly and accurately identify tumor-related genetic mutations that can ...
(Date:5/15/2017)... ... May 15, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that it has signed ... diseases, to support preclinical and clinical development of TA-46, a novel protein addressing ...
Breaking Biology Technology:
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
Breaking Biology News(10 mins):